Abstract: Disclosed herein are macrocyclic polypeptides having no more than 3 ammo acid substitutions compared to the amino acid sequence of any one of SEQ ID NO: 1-2.37 or a mirror image thereof, wherein the polypeptide includes both L and D amino acids, libraries of such polypeptides, and uses thereof.
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
December 13, 2022
Assignee:
University of Washington
Inventors:
Parisa Hosseinzadeh, David Baker, Gaurav Bhardwaj, Vikram K. Mulligan
Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.
Abstract: Disclosed are compositions and methods useful for oral delivery of targeted therapies for pulmonary diseases, fibrotic disorders and cancer. The compositions and methods are based on peptide sequences that selectively bind to and home to diseased tissue and enable targeted therapies to affect a beneficial therapeutic result. The disclosed targeting is useful for oral delivery of therapeutic and detectable agents to diseased tissue in an animal.
Abstract: The present technology provides methods end medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] to a subject suffering from prostate cancer or breast cancer.
Type:
Grant
Filed:
October 16, 2020
Date of Patent:
November 29, 2022
Assignees:
UNIVERSITY OF KANSAS, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
Jane Aldrich, Archana Mukhopadhyay, Laura E. Hanold
Abstract: The present invention relates to a method for removing water from a compound solution and performing conjugate acid conversion. The method uses a nanometer film to perform reverse osmosis for the compound solution to remove water, and provides a conjugate acid to replace the acidic substances in the compound solution in order to obtain compound conjugate acid salts. The method of the present invention can effectively reduce the water content of the compound solution and replace the conjugate acid of the compound to form the desired compound conjugate acid salt.
Type:
Grant
Filed:
February 24, 2021
Date of Patent:
November 29, 2022
Assignee:
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD.
Inventors:
Yao-Lung Hsu, Kuang-Chan Hsieh, Hui-Wen Cheng, Zong-Han Yang
Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
November 22, 2022
Assignees:
Merck Sharp & Dohme LLC, Ra Pharmaceuticals, Inc.
Inventors:
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Ketki Ashok Dhamnaskar, Zhong Ma, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Aurash Shahripour, Yusheng Xiong
Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
Type:
Grant
Filed:
July 15, 2019
Date of Patent:
November 22, 2022
Assignee:
Rosalind Franklin University of Medicine and Science
Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (Accession number: KCTC 12854BP), which has the ability to kill Enterococcus faecium and an amino acid sequence represented by SEQ ID NO: 2, a pharmaceutical composition containing the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium using the pharmaceutical composition.
Type:
Grant
Filed:
November 20, 2020
Date of Patent:
November 8, 2022
Assignee:
INTRON BIOTECHNOLOGY, INC.
Inventors:
Seong Jun Yoon, Myung Soo Kang, Soo Youn Jun, Jong Hyun Kim, Gi Mo Jung, Jee Soo Son, Hyoun Rok Paik, Sang Hyeon Kang
Abstract: The present invention provides a synergistic composition of a nematicide comprising of a nematicidal peptides derived from CED-4 protein sequence comprising of at least two peptides. The nematicidal peptides individually show 100% nematicidal activity at a concentration of 1 mg/ml, whereas, the combination of at least two peptides in a ratio of 1:1 shows 100% nematicidal activity at concentration as low as 0.8 mg/ml bringing a synergistic effect. This synergistic nematicidal composition is highly economical as it requires 20% less peptide concentration for 100% activity, moreover the composition is environmentally safe and non-toxic to humans and animals.
Type:
Grant
Filed:
March 17, 2018
Date of Patent:
November 1, 2022
Assignee:
TELLURIS BIOTECH INDIA PRIVATE LIMITED
Inventors:
Venu Polineni, Alejandro Calderón Urrea, Glenda W. Polack
Abstract: The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
February 14, 2017
Date of Patent:
November 1, 2022
Assignee:
AbbVie Inc.
Inventors:
Walid M. Awni, Barry M. Bernstein, Andrew L. Campbell, Sandeep Dutta, Chih-Wei Lin, Wei Liu, Rajeev M. Menon, Sven Mensing, Thomas J. Podsadecki, Tianli Wang
Abstract: The present disclosure relates to compositions and methods for inhibiting L-plastin activity for inhibiting bone resorption activity of osteoclasts. In certain instances, the compositions and methods are used to treat or prevent a disease or disorder associated with bone resorption. In one aspect, the compositions and methods relate to peptide inhibitors comprising an N-terminal fragment of L-plastin.
Abstract: The present invention relates to methods and compounds for treating or preventing cancer. Methods and compositions provided include including inhibiting or suppressing the development, maintenance, and proliferation of cancers, including blocking or inhibiting cancer cell metastasis.
Type:
Grant
Filed:
June 12, 2020
Date of Patent:
October 11, 2022
Assignees:
BIOMARCK PHARMACEUTICALS LTD., NORTH CAROLINA STATE UNIVERSITY
Abstract: Disclosed herein are antigen-capturing nanoparticles. Specifically, the subject matter contained herein pertains to novel nanoparticles that can capture a multitude of tumor antigens that are released from tumor cells. Also, provided herein are methods for preparing the antigen-capturing nanoparticles and methods for the treatment of disease in a subject comprising administering the antigen-capturing nanoparticles.
Type:
Grant
Filed:
November 17, 2016
Date of Patent:
September 20, 2022
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Andrew Wang, Yuanzeng Min, Zach Rodgers
Abstract: A synthetic platelet including a biocompatible flexible nanoparticle, the nanoparticle having an outer surface and a plurality of site targeted peptides conjugated to the surface, the synthetic platelet also including a therapeutic agent, wherein the therapeutic agent is encapsulated by the nanoparticle, wherein the synthetic platelet adheres to the site targeted and promotes delivery of the therapeutic agent onto sites of the synthetic platelet adhesion, and wherein the therapeutic agent is released at the site targeted via a site-relevant enzyme.
Abstract: A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
Abstract: The invention relates to a composition of peptides having an aminogram in which: glycine, hydroxyproline and proline are in molar quantities such that the ratio of each quantity to the sum of the molar quantities of the amino acids in the composition is comprised between 20.0% and 24.5%, between 6.0% and 12.0% and between 10.6% and 14.6%, respectively; the peptide composition comprising a quantity of peptides with a molecular weight lower than 1400 Da such that the ratio of said quantity to the quantity of peptides in the composition is less than 40%; the molecular weight and the quantity of peptides in the composition being determined by exclusion chromatography. The invention likewise relates to such a composition to be used as a drug. The invention further relates to such a composition to be used as a food supplement.
Abstract: A novel peptide and a composition including the peptide are disclosed. The composition may be a pharmaceutical composition, a quasi-drug composition, a dietary supplement, or a food composition. A polynucleotide encoding the peptide and an expression vector including the polynucleotide are also disclosed. The peptide promotes regeneration of hard tissue and is useful for treating dentin-dental pulp diseases or periodontal diseases.